Elacestrant in ER+/HER2- mBC: Overview of the EMERALD subgroup analysis

8 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
In this clinical topic video, Professor of Medicine Dr Virginia Kaklamani shares her insights on the recent publication of the subgroup analyses from the phase III EMERALD Trial by prior duration of endocrine therapy plus CDK4/6 inhibitor.

 

Dr Kaklamani highlights elacestrant's place in the treatment landscape for ER+/HER2- metastatic breast cancer. 

 

Clinical takeaways

Elacestrant provides a PFS benefit for patients with ER+/HER2- mBC who received at least 12 months of ET+CDK4/6i in 1L and whose tumours harbour ESR1-mut with a favourable safety profile

ESR1-mut testing should be done at 1L progression via liquid biopsy due to disease subclonality; if negative, repeat at each progression. Archival tissue should not be used for testing due to the acquired nature of ESR1-mut

Elacestrant provides significant PFS benefits in ER+/HER2- metastatic tumours harbouring coexisting ESR1 and PIK3CA-mut, indicating that disease progression after ET+CDK4/6i in this subgroup may remain ER-driven. Safety analyses demonstrated that elacestrant had a manageable safety profile similar to other ETs

   

Learn more and download the accompanying slide deck here https://cor2ed.com/n-connect/programmes/elacestrant-er-her2-metastatic-breast-cancer/

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.



This video was developed by COR2ED Medical Affairs



Published December 2024
Category
Oncology
Be the first to comment

Up Next